ea0029p700 | Diabetes | ICEECE2012
Dicembrini I.
, Di Pasquale G.
, Raimondi L.
, Pagano C.
, Egan J.
, Cozzi A.
, Cinci L.
, Manni E.
, Loreto A.
, Berretti S.
, Morelli A.
, Baum B.
, Maggi M.
, Vettor R.
, Chiorini J.
, Rotella C.
, Mannucci E.
Background: Exendin-4 (Ex-4) is a GLP-1 receptor agonist approved for the treatment of Type 2 Diabetes (T2DM). Aim of this study was to characterize the effects of Ex-4 expressed continuously from salivary glands (SG), following adeno-associated virus-mediated (AAV) gene therapy in two different model of obesity and T2DM. Several trials support an AAV good safety and little toxicity profile. Serotype 5 (AAV5) presented enhanced gene transfer activity in SG and an efficient pro...